ArticleHealth science reports2026
Artificial Intelligence and Prostate-Breast Cancer Biology: Recent Advances in Treatments and Perspectives - A Comprehensive Review.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: The therapeutic limitations of conventional cancer treatment currently deployed are driving the development and creation of new nano-drugs. Prostate cancer (PCa) is a prevalent clinical problem in older men with a significant global incidence, with 1.5 million cases reported in 2022. Breast cancer (BC) is also a considerable health burden among women worldwide, with reports showing over 67,000 deaths in 2022. Generally, across the world, cancer has posed significant health burden due to limited access to treatment options, high incidence rates, and mortality rates occasioned by lifestyle and genetic factors. This review explores the potential of nanomedicine and artificial intelligence (AI) to overcome these limitations and improve patient outcomes, and provides an insightful overview of the available cancer treatment options, such as radiation therapy, surgery, hormone therapy, chemotherapy, and targeted therapies, focusing on PCa and BC. Methods: A comprehensive synthesis of recent literature has been conducted, focusing on enormous advances that have been made to understand the biology of various cancers, imaging technologies, and therapeutic approaches. Subsequently, cancer management has evolved rapidly, focusing on the genomic landscape and oncogenesis of localized and metastatic cancers. Results: The current treatment strategies face therapeutic challenges related to accessibility issues, drug resistance, and side effects. The emergence of nanomedicine and artificial intelligence (AI) models in imaging, therapy, and drug delivery offers solutions related to these challenges. Nanomedicine is a growing research hotspot with an increased number of publications with keywords such as "prodrug," "cancer nanomedicine," "cancer immunotherapy," "artificial intelligence," and "targeted nanomedicine". Conclusions: The nanotechnologies utilized in cancer treatment reduce side effects, enhance treatment efficacy, and improve patient outcomes. Combining nanomedicine with conventional therapies holds promise in revolutionizing cancer treatment and addressing the clinical challenges of current therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.